Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity

Childhood onset neurofibromatosis type 2 can be severe and genotype dependent. We present a retrospective phenotypic analysis of all ascertained children in England 1.0). Focal cortical dysplasia occurred in 26% group 3 and 4% 2A. A total of 48% of group 3 underwent ≥1 major intervention (intracranial/spinal surgery/Bevacizumab/radiotherapy) compared to 35% of 2A; with 23% group 3 undergoing spinal surgery (schwannoma/ependymoma/meningioma resection) compared to 4% of 2A. Mean age starting Bevacizumab was 12.7 in group 3 and 14.9 years in 2A. In conclusion, group 3 phenotype manifests earlier with greater tumour load, poorer visual outcomes and more intervention.

[1]  D. Halliday,et al.  Neurofibromatosis Type 2–Related Eye Disease Correlated With Genetic Severity Type , 2019, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[2]  D. Halliday,et al.  Progression of hearing loss in neurofibromatosis type 2 according to genetic severity , 2018, The Laryngoscope.

[3]  M. Kellett,et al.  High‐Grade Glioma is not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient , 2018, Neurosurgery.

[4]  D. Evans,et al.  Schwannomatosis: a genetic and epidemiological study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  A. Siddiqui,et al.  Cerebral vasculopathy in childhood neurofibromatosis type 2: cause for concern? , 2018, Developmental medicine and child neurology.

[6]  D. Halliday,et al.  Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population , 2018, Archives of Disease in Childhood.

[7]  D. Evans,et al.  Hearing optimisation in neurofibromatosis type 2: A systematic review , 2017, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[8]  D. Evans,et al.  Genetic Severity Score predicts clinical phenotype in NF2 , 2017, Journal of Medical Genetics.

[9]  M. Giovannini,et al.  A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas , 2017, Journal of Neuro-Oncology.

[10]  C. Chung,et al.  Genetic differences on intracranial versus spinal cord ependymal tumors: a meta-analysis of genetic researches , 2016, European Spine Journal.

[11]  E. Harkness,et al.  The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes , 2016, Human mutation.

[12]  D. Evans,et al.  Neurofibromatosis type 2 service delivery in England. , 2016, Neuro-Chirurgie.

[13]  D. G. Evans,et al.  Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms. , 2015, Seminars in pediatric neurology.

[14]  David Evans,et al.  Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients , 2015, Journal of Medical Genetics.

[15]  D. Evans,et al.  Bilateral vestibular schwannomas in older patients: NF2 or chance? , 2015, Journal of Medical Genetics.

[16]  N. Bonne,et al.  Causes of mortality in neurofibromatosis type 2 , 2015, British journal of neurosurgery.

[17]  A. Muzikansky,et al.  Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients , 2014, Cancer Chemotherapy and Pharmacology.

[18]  D. Evans,et al.  Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2 , 2014, Journal of Neurology.

[19]  K. Ohno,et al.  Characterization of early onset neurofibromatosis type 2 , 2014, Brain and Development.

[20]  A. Wallace,et al.  Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity , 2013, Clinical genetics.

[21]  A. Quattrone,et al.  Natural history of neurofibromatosis type 2 with onset before the age of 1 year , 2013, neurogenetics.

[22]  D. Evans,et al.  Genetic testing and screening of individuals at risk of NF2 , 2012, Clinical genetics.

[23]  A. B. Grayeli,et al.  Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. , 2012, Neuro-oncology.

[24]  W. Curry,et al.  Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. , 2011, Journal of neurosurgery. Spine.

[25]  D. Evans,et al.  Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset , 2011, Journal of Medical Genetics.

[26]  R. Ferner,et al.  A qualitative study of the impact of living with neurofibromatosis type 2 , 2011, Psychology, health & medicine.

[27]  A. Shenton,et al.  Further genotype – phenotype correlations in neurofibromatosis 2 , 2009, Clinical genetics.

[28]  M. Lev,et al.  Concordance of Bilateral Vestibular Schwannoma Growth and Hearing Changes in Neurofibromatosis 2: Neurofibromatosis 2 Natural History Consortium , 2009, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[29]  D. Evans,et al.  Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification , 2007, Journal of Medical Genetics.

[30]  E. Boltshauser,et al.  Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. , 2006, American journal of ophthalmology.

[31]  D. Stephens,et al.  Psychosocial effects of neurofibromatosis type 2 (Part 1): General effects , 2006 .

[32]  D. Evans,et al.  Management of the patient and family with neurofibromatosis 2: a consensus conference statement , 2005, British journal of neurosurgery.

[33]  A. Polizzi,et al.  Earliest Clinical Manifestations and Natural History of Neurofibromatosis Type 2 (NF2) in Childhood: A Study of 24 Patients* , 2005, Neuropediatrics.

[34]  D. Evans,et al.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. , 2004, American journal of human genetics.

[35]  M. Maccollin,et al.  Neurofibromatosis 2 in the Pediatric Population , 2003, Journal of child neurology.

[36]  D. Evans,et al.  Predictors of the risk of mortality in neurofibromatosis 2. , 2002, American journal of human genetics.

[37]  L. Kluwe,et al.  Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study. , 2002, Journal of neurosurgery.

[38]  J. Jääskeläinen,et al.  Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus , 2000, Neurology.

[39]  D. Evans,et al.  Paediatric presentation of type 2 neurofibromatosis , 1999, Archives of disease in childhood.

[40]  V. Mautner,et al.  The diagnosis and management of neurofibromatosis 2 in childhood. , 1998, Seminars in pediatric neurology.

[41]  L. Kluwe,et al.  Mosaicism in sporadic neurofibromatosis 2 patients. , 1998, Human molecular genetics.

[42]  D. Evans,et al.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. , 1998, Journal of medical genetics.

[43]  M. Tatagiba,et al.  Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. , 1998, American journal of medical genetics.

[44]  L. Kluwe,et al.  Skin abnormalities in neurofibromatosis 2. , 1997, Archives of dermatology.

[45]  L. Kluwe,et al.  Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes , 1996, Human Genetics.

[46]  R. Weksberg,et al.  Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. , 1996, American journal of human genetics.

[47]  S. Pulst,et al.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 , 1993, Nature.

[48]  D. Evans,et al.  A clinical study of type 2 neurofibromatosis. , 1992, The Quarterly journal of medicine.

[49]  D. Evans,et al.  Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort , 2016, Journal of Neuro-Oncology.

[50]  S. Pulst,et al.  Neurofibromatosis 2 in the pediatric age group. , 1993, Neurosurgery.